C S Voican1, O Mir2, P Loulergue3, M Dhooge1, C Brezault1, J Dréanic1, S Chaussade1, S Pol4,5, R Coriat1. 1. Gastro-Enterology and Digestive Oncology Unit, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris. 2. Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif olivier.mir@gustaveroussy.fr. 3. CIC Vaccinologie, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris. 4. Hepatology Unit, Cochin Teaching Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris. 5. Inserm USM20, Institut Pasteur, Paris, France.
Abstract
BACKGROUND: Hepatitis B virus (HBV) reactivation is a well-known risk during chemotherapy for hematological malignancies with reported rates ranging between 14% and 72%. However, there is a paucity of data regarding HBV infection management and reactivation risk in patients receiving systemic treatments for solid tumors. DESIGN: We conducted a PubMed search for publications from January 1990 until May 2016 related to HBV reactivation. The search terms were 'hepatitis B reactivation', cross-referenced with 'chemotherapy', then 'hepatitis B' cross-referenced with International Non-proprietary Name of each of the most used chemotherapy drugs in solid tumors. RESULTS: From these data, a grading of HBV reactivation risk and recommendations for management are given for most frequently used anticancer drugs in solid tumors. CONCLUSION: Most drugs used for the treatment of solid tumors can induce hepatitis B reactivation in HBs antigen-positive patients. HBV screening can be recommended before systemic treatment initiation. Pre-emptive antiviral treatment can reduce the risk of HBV reactivation and prevent chemotherapy disruption.
BACKGROUND:Hepatitis B virus (HBV) reactivation is a well-known risk during chemotherapy for hematological malignancies with reported rates ranging between 14% and 72%. However, there is a paucity of data regarding HBV infection management and reactivation risk in patients receiving systemic treatments for solid tumors. DESIGN: We conducted a PubMed search for publications from January 1990 until May 2016 related to HBV reactivation. The search terms were 'hepatitis B reactivation', cross-referenced with 'chemotherapy', then 'hepatitis B' cross-referenced with International Non-proprietary Name of each of the most used chemotherapy drugs in solid tumors. RESULTS: From these data, a grading of HBV reactivation risk and recommendations for management are given for most frequently used anticancer drugs in solid tumors. CONCLUSION: Most drugs used for the treatment of solid tumors can induce hepatitis B reactivation in HBs antigen-positive patients. HBV screening can be recommended before systemic treatment initiation. Pre-emptive antiviral treatment can reduce the risk of HBV reactivation and prevent chemotherapy disruption.
Authors: Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong Journal: Hepatology Date: 2018-04 Impact factor: 17.425
Authors: Kelly R Long; Elena Lomonosova; Qilan Li; Nathan L Ponzar; Juan A Villa; Erin Touchette; Stephen Rapp; R Matt Liley; Ryan P Murelli; Alexandre Grigoryan; R Mark Buller; Lisa Wilson; John Bial; John E Sagartz; John E Tavis Journal: Antiviral Res Date: 2017-11-10 Impact factor: 5.970
Authors: Andrea Antonuzzo; Fabio Calabrò; Pietro Quaglino; Fausto Roila; Gian Domenico Sebastiani; Francesco Spina; Giuseppe Pasqualetti; Diego Cortinovis; Enrico Tagliaferri; Alessandro Peri; Elena Margherita Presotto; Maria Francesca Egidi; Luca Giacomelli; Ferruccio Farroni; Massimo Di Maio; Emmanuele De Luca; Marco Danova; Florian Scottè; Karin Jordan; Paolo Bossi Journal: Oncologist Date: 2020-03-17
Authors: Jessica P Hwang; Anna S Lok; Michael J Fisch; Scott B Cantor; Andrea Barbo; Heather Y Lin; Jessica T Foreman; John M Vierling; Harrys A Torres; Bruno P Granwehr; Ethan Miller; Cathy Eng; George R Simon; Sairah Ahmed; Alessandra Ferrajoli; Jorge Romaguera; Maria E Suarez-Almazor Journal: J Clin Oncol Date: 2018-02-15 Impact factor: 50.717